High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.
about
Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generationOn the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation.The use of recombinant activated coagulation factor VII for spine surgeryRecombinant activated factor VII in patients at high risk of bleeding.Diminished response to recombinant factor VIIa in a patient with idiopathic thrombocytopenic purpura.Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts.Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopeniaEmergency reversal of pentasaccharide anticoagulants: a systematic review of the literature.Potential role for rFVIIa in transfusion medicine.Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.Investigation into the effects of antioxidant-rich extract of Tamarindus indica leaf on antioxidant enzyme activities, oxidative stress and gene expression profiles in HepG2 cellsIntraoperative pediatric blood transfusion therapy: a review of common issues. Part II: transfusion therapy, special considerations, and reduction of allogenic blood transfusions.Recombinant activated factor VII and the anaesthetist.A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions.Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.Recombinant-activated coagulation factor VIIa (NovoSeven): current development.FVIIa as used pharmacologically is not TF dependent in hemophilia B miceOptimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.Recombinant Factor VIIa for Bleeding in Non-hemophiliac Pediatric Patients.Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.Platelet activation and aggregation: the importance of thrombin activity--a laboratory model.The influence of coagulation and inflammation research on the improvement of polytrauma care.Recombinant factor VIIa: hemostatic adjunct in the coagulopathic burn patient.Management of life-threatening hemorrhages and unsafe interventions in nonhemophiliac children by recombinant factor VIIa.Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation.Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist.A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.Correlation of thromboelastographic patterns with clinical presentation and rationale for use of antifibrinolytics in severe haemophilia patients.Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia.The use of recombinant factor VIIa for bleeding in paediatric practice.High dose factor VIIa improves clot structure and stability in a model of haemophilia B.Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants.Vascular injury and thrombotic potential: a note of caution about recombinant factor VIIa.Intrapulmonary rFVIIa for life threatening pulmonary hemorrhage in a case of relapsing acute lymphoblastic leukemia and platelet refractoriness.Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.
P2860
Q28200448-F48B7EC8-0598-40E6-8D91-8A636C8465A7Q33342552-60414271-0150-462B-B074-89D8D4583A2DQ33360946-2E866A68-6B6E-48F9-A2A2-777A5EB59C9BQ33365354-B17EC6AE-0196-4B72-AB15-837BE38019A9Q33373076-527DCDE1-581E-477A-B647-5574B972DEDCQ33382014-CF770850-B507-455C-9729-0566B8F088F4Q33404353-CAF3EE65-31EA-4DDB-8F72-6F1BECB119CAQ33429950-DA7F6A26-F0DC-4843-AE16-BD8E523A81B2Q34101751-8EA3F563-A075-4E63-BD4B-0F2BFA59D6F7Q34564930-69FF6092-3646-4CDD-9E41-FE1C967832C5Q35839531-93E0B67C-2BA0-47C5-ABEA-FCE68D5F746CQ36257914-E7459F9D-D2B5-41AB-BB1D-ACBD4154A9AFQ36263592-4366E7CD-DF6B-4532-95D7-A79200B8987CQ36313315-93BE5DE1-C0D3-4967-A4E1-3C8002299E57Q36462093-F5651730-2C19-4A72-BF34-02E5B09D8A75Q36492564-6EB9B209-8188-4955-89BB-A54EA3401E81Q36570888-8782EDE7-6034-40BA-8710-FCCCAB4DA103Q36800526-513411A2-2564-4DCE-87AD-CE12A7A1FC5DQ37636989-8D293D62-DB45-4412-8628-E22FF8B6E62CQ37778292-813CDE1C-0FE2-47DA-8860-31F928EEC108Q38051320-5A5139BB-3C54-44D1-9861-B0724A1328DDQ38209486-9B7BE817-A728-41AE-9452-70F75FBB8877Q39471623-4EDB61E8-FA84-4CB8-BC8D-5E1E8265CC1AQ39611127-D8EDDCA5-962E-4190-A8A5-1F0AA354251FQ42018362-DD1D19A7-8756-47F0-B71F-FEBFC39A9241Q43664321-1A106EBB-A2C2-4598-AA04-C435E93E3BE4Q45856010-F05D7BDB-B284-4CA7-94D8-44255CFCAA54Q45863892-41DE0A33-B5ED-4948-B171-1C4F88C3DFF5Q45865116-CBEFA6C1-5599-4AF8-B9B8-DBD18EE8A36AQ45868696-A0D9FFCD-3215-43BC-B1B6-3EF34CEAF8AEQ45872342-93A5FA09-5AF7-498A-9020-584FE1879317Q45872851-A5E9674F-1C36-4D35-BBD8-4BFE1DEA3A4AQ45877685-8DC97611-D327-4226-929A-DC4DD31F0634Q45880844-AD0FB345-34AE-4874-A47A-17441BE842BBQ45882489-209A815B-50D6-4E71-BB59-4829368F2F63Q45889198-736B2802-53A9-4F67-9D5B-922C0BFD2E6DQ47174603-9EFF6828-4933-4F46-BC85-E60EAD914F2CQ48519248-856EF68C-C517-45F5-A1E7-FFA13FACED2AQ50485037-219A5817-B73D-4F83-94C3-7CE2ADE5121FQ50653679-9B7D0755-3C20-44BC-B837-8628B3AE8B8B
P2860
High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
High-dose factor VIIa increase ...... in a cell-based model system.
@ast
High-dose factor VIIa increase ...... in a cell-based model system.
@en
High-dose factor VIIa increase ...... in a cell-based model system.
@nl
type
label
High-dose factor VIIa increase ...... in a cell-based model system.
@ast
High-dose factor VIIa increase ...... in a cell-based model system.
@en
High-dose factor VIIa increase ...... in a cell-based model system.
@nl
prefLabel
High-dose factor VIIa increase ...... in a cell-based model system.
@ast
High-dose factor VIIa increase ...... in a cell-based model system.
@en
High-dose factor VIIa increase ...... in a cell-based model system.
@nl
P2093
P2860
P1476
High-dose factor VIIa increase ...... s in a cell-based model system
@en
P2093
P2860
P304
P356
10.1046/J.1365-2141.2001.02870.X
P407
P577
2001-07-01T00:00:00Z